Pegilated interferon α2а in treatment of chronic hepatitis C
Abstract
Aim of investigation. To analyze experience of pegIFN-α 2а (Pegasys®) application at combined antiviral therapy of chronic hepatitis C (CHC) within the framework of the Moscow regional regional program on viral hepatites treatment.
Material and methods. Overall 369 patients underwent treatment since 2008 to 2011, of them 292 patients – with CHC. Male patients prevailed in the studied group – 202 (54,74%), female patients – 167 (45,26%), mean age was 41,1 years. Prior to therapy onset needle liver biopsy was carried out in 88,3% of patients, subsequently liver cirrhosis was diagnosed in 77 patients. In 227 of patients the 1-st HCV genotype was revealed, 2nd genotype – in 24, 3rd genotype – in 41cases.
Results. Sustained virologic response (SVR) after the termination of antiviral therapy was achieved in 70,1% of patients. Statistically significant differences by gender, body mass index, virus genotype were revealed between groups which have achieved and not achieved SVRs. Anemia, leukopenia, thrombocytopenia, thyropathy and depression were marked as the most frequent undesirable treatment effects.
Conclusions. Follow-up of CHC patients, treated by pegIFN-α2а and ribavirin in the Moscow regional hepatological center, testifies its high efficacy and safety profile.
About the Authors
P. O. Bogomolov
МОНИКИ им. М.Ф. Владимирского
Russian Federation
Russian Federation
S. V. Koblov
МОНИКИ им. М.Ф. Владимирского
Russian Federation
Russian Federation
A. O. Buyeverov
ГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздравсоцразвития РФ
Russian Federation
Russian Federation
M. V. Matsiyevich
МОНИКИ им. М.Ф. Владимирского
Russian Federation
Russian Federation
O. S. Kuzmina
МОНИКИ им. М.Ф. Владимирского
Russian Federation
Russian Federation
N. A. Barsukova
МОНИКИ им. М.Ф. Владимирского
Russian Federation
Russian Federation
N. V. Dubinina
МОНИКИ им. М.Ф. Владимирского
Russian Federation
Russian Federation
References
1. Богомолов П.О., Буеверов А.О. Эффективность и безопасность комбинированной терапии отечественными противовирусными препаратами хронического гепатита С // Фарматека – 2006. – № 5. – С. 28–32.
2. Богомолов П.О., Буеверов А.О., Дубинина Н.В. и др. Эффективность лечения больных хроническим гепатитом С с 1-м генотипом вируса стандартным интерфероном альфа // Клин. перспект. гастроэнтерол. гепатол. – 2011. – № 6. – С. 17–22.
3. Богомолов П.О., Буеверов А.О., Кузьмина О.С., Мациевич М.В. Влияние метформина на эффективность противовирусной терапии у больных хроническим гепатитом С с 3-м генотипом вируса (предварительные результаты) // Клин. перспект. гастроэнтерол. гепатол. – 2010. – № 4. – С. 32–39.
4. Корочкина О.В., Гейвандова Н.И., Ратникова Л.И. и др. Эффективность и безопасность препарата Альтевир при лечении больных хроническим гепатитом С // Клин. перспект. гастроэнтерол. гепатол. – 2009. – № 4. – С. 22–28.
5. Рациональная фармакотерапия в гепатологии / Под ред. В.Т. Ивашкина, А.О. Буеверова. – М.: Литтерра, 2009.
6. Ascione A., de Luca M., Tartaglione M.T. et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection // Gastroenterology. – 2010. – Vol. 138. – P. 116–122.
7. Backus L.I., Boothroyd D.B., Phillips B.R., Mole L.A. Predictors of response of US veterans to treatment for the hepatitis C virus // Hepatology. – 2007. – Vol. 46. – P. 37–47.
8. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003 (http://ctep. cancer.gov), Publish Date: August 9, 2006
9. Fried M.W., Shiffman M.L., Reddy K.R. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection // N. Engl. J. Med. – 2002. – Vol. 347. – P. 975–982.
10. Leise M.D., Kim W.R., Canterbury K.M., Poterucha J.J. Drug therapy: telaprevir // Hepatology. – 2011. – Vol. 54. – P. 1463–1469.
11. Lindsay K.L, Trepo C., Heintges T. et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C // Hepatology. – 2001. – Vol. 34. – P. 395–403.
12. McHutchison J.G., Lawitz E.J., Shiffman M.L. et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection // N. Engl. J. Med. – 2009. – Vol. 361. – P. 580–593.
13. Rosen H.R. Chronic hepatitis C infection. Clinical practice // N. Engl. J. Med. – 2011. – Vol. 364. – Р. 2429–2438. Protease inhibitors for treatment of genotype 1 hepatitis C virus infection.
14. Tsubota A., Fujise K., Namiki Y., Tada N. Peginterferon and ribavirin treatment for hepatitis C virus infection // World J. Gastroenterol. – 2011. – Vol. 17. – P. 419– 432.
15. Zaman A., Fennerty M.B., Keeffe E.B. Systematic review: peginterferon vs. standard interferon in the treatment of chronic hepatitis C // Aliment. Pharmacol. Ther. – 2003. – Vol. 18. – P. 661–670.
Review
For citations:
Bogomolov P.O., Koblov S.V., Buyeverov A.O., Matsiyevich M.V., Kuzmina O.S., Barsukova N.A., Dubinina N.V. Pegilated interferon α2а in treatment of chronic hepatitis C. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2012;22(5):64-68. (In Russ.)
Views:
68
Email this article 
